By Marshall Weiss, The Dayton Jewish Observer (reprinted with permission) | May 06, 2021
In an operating room at Dayton Children’s Hospital on April 8, 4-year-old Benny Landsman of Brooklyn received the first new clinical trial of an FDA-approved gene therapy for Canavan disease.
Neurosurgeon Dr. Robert Lober placed four catheters in holes drilled into Benny’s skull, down a track to a fluid space in the brain’s ventricles. Lober then manually injected a fluid containing 370 trillion viral genomes of the new therapy.
By his side in the operating room were the trial’s clinical leader, Dr. Christopher G. Janson, also with Dayton Children’s and Premier Health’s Clinical Neuroscience Institute, and longtime Canavan researcher Paola Leone, professor of cell biology at Rowan University in Glassboro, New Jersey, and director of Rowan’s Cell and Gene Therapy Center.
By Joseph Walker Health officials around the country resumed offering Johnson & Johnson s Covid-19 vaccine this weekend after getting a green light from federal regulators on Friday. The U.S. Food and Drug Administration and U.S. Centers for Disease Control and Prevention lifted their recommendation to pause the shots after investigating reports of rare but potentially dangerous blood clotting in certain recipients. On Friday, FDA and CDC officials said inoculations could continue because their benefits outweigh their risks. The FDA issued updated informational guides that inform vaccine recipients and doctors of the risk of a blood-clotting side effect that has primarily affected adult women under 50. The overall risk is about 1.9 cases per million people, though the risk is about 3.5 times higher for women ages 18 to 49, officials said.
By Joseph Walker Health officials around the country are preparing to resume offering Johnson & Johnson s Covid-19 vaccine as soon as this weekend after getting a green light from federal regulators on Friday. The U.S. Food and Drug Administration and U.S. Centers for Disease Control and Prevention lifted their recommendation to pause the shots after investigating reports of rare but potentially dangerous blood clotting in certain recipients. On Friday, FDA and CDC officials said inoculations could continue because their benefits outweigh their risks. Vaccinations can begin as soon as Saturday morning, said FDA s vaccines chief Peter Marks on a conference call with reporters Friday. The FDA issued updated informational guides that inform vaccine recipients and doctors of the risk of a blood-clotting side effect that has primarily affected adult women under 50. The overall risk is about 1.9 cases per million people, though the risk is about 3.5 times higher for wo
Skip to main content
A top doc at Yale New Haven Hospital is worried about CT not reaching COVID herd immunity
Brian Zahn
FacebookTwitterEmail
1of3
New Haven, Connecticut - Tuesday, October 27, 2020: Yale New Haven Hospital.Peter Hvizdak / Hearst Connecticut MediaShow MoreShow Less
2of3
The front entrance of Yale New Haven Hospital in New Haven photographed on May 13, 2020.Arnold Gold / Hearst Connecticut MediaShow MoreShow Less
3of3
NEW HAVEN Reporting a “slack in demand” for vaccines that protect against COVID-19, a top medical official with the Yale New Haven Health system said he is “worried” about the state reaching herd immunity.
“Right around 55 percent of the state vaccinated: half is there and half has not yet been vaccinated,” said Yale New Haven Heath Chief Clinical Officer Dr. Thomas Balcezak.